RECENT ADVANCE IN DIABETES: INNOVATION, CHALLENGES AND FUTURE DIRECTION
Main Article Content
Keywords
Diabetes Management, Insulin Delivery systems, Gene theraphy, continuous Glucose Monitoring(CGM)
Abstract
Diabetes remains a significant global health challenge, characterized by rising prevalence, complex management needs, and a substantial burden on healthcare systems. Recent advances in diabetes research have introduced innovative approaches aimed at improving patient outcomes, yet numerous challenges persist. This review explores these advancements, focusing on the latest innovations in pharmacotherapy, technological interventions, and personalized care strategies. Notable developments include the introduction of SGLT-2 inhibitors and GLP-1 receptor agonists, which have shown promise in not only managing blood glucose levels but also reducing cardiovascular risks in patients with type 2 diabetes. Additionally, advancements in continuous glucose monitoring (CGM) and insulin delivery systems, including artificial pancreas technologies, have significantly improved glycemic control and quality of life for patients. However, these innovations come with challenges such as high costs, limited access in low-resource settings, and the need for widespread education and training. The review also addresses the integration of digital health solutions, including mobile health applications and telemedicine, which have the potential to enhance patient engagement and adherence to treatment. Looking to the future, the focus will likely shift towards the implementation of precision medicine, leveraging advances in genomics and bioinformatics to create tailored treatment plans that account for individual variability. Overcoming existing barriers, such as ensuring equitable access to these new technologies and addressing socioeconomic disparities, will be critical to realizing the full potential of these innovations. This article provides a critical overview of the recent advances, ongoing challenges, and future directions in diabetes research and care.
References
2. M. Wang, P. Yao, M. Gao, J. Jin and Y. Yu, “Novel fatty chain-modified GLP-1R G-protein bias agonist exerts prolonged anti-diabetic effects through targeting receptor binding sites”, RSC Adv., 2020,(10), 8044–8053.
3. Brussels, Belgium:International Diabetes Federation; 20134. Nathan DM .Long-term complications of diabetes mellitus.N Engl J Med.2019,1993;328(23):1676-1685.
4. Atlanta, GA: “Dept of Health and Human Services, Centers for Control and Prevention.” Prediabetes in the United States;2011,1855-1860.
5. PreisSR, HwangSJ, CoadyS, etal . “Trendsin all-cause and cardio vascular disease mortalit among women and men with and without dtiabetes mellitus in the Framingham.” Heart Study Circulation.2009;119(13):1728-1735.
6. Harding JL,ShawJE, PeetersA, CartensenB, “Magliano DJ. Cancerrisk among people with type1 andtype2diabetes.” Diabetes Care.2015;38(2): 264-270.
7. DallTM, YangW, HalderP, etal. “Theeconomic burden of elevated blood glucose levels in Diabetes Care” patient Educ couns.2014;37(12):3172-3179.
8. Galindo RJ, Aleppo G. “ Continuous Glucose Monitoring: the achievement of 100 years of innovation in diabetes technology.”Diabetes Res Clin Pract. 2020.(12)108-502.
9. Huxley RR, Peters SA, Mishra GD, Woodward M. “Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis.”Lancet Diabetes Endocrinol.2015;3(3):198-206.
10. Atkinson MA. Thirty years of investigating the autoimmune basis for type 1 diabetes. Diabetes.salud publica mex 2005;(54):1253–1263
11. Morales A. “A better future for children with type 1 diabetes: Review of the conclusions from the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications study”. J Ark Med Soc.2009;106-108
12. Furth ME, Atala A. “Stem cell sources to treat diabetes.” J Cell Biochem. 2009; (11)106:507–11.
13. Couri CE, Voltarelli JC. “Autologous stem cell transplantation for early type 1 diabetes mellitus”. Autoimmunity. 2008;(41):666-672.
14. S. D. Brugger, L. Bomar and K. P. Lemon, “Commen salpathogen interactions along the human nasal passage.s” PLoS Pathog., 2016, (12),100-105.
15. Buchanan, T.A.; Xiang, A.H.; Page, K.A. Gestational Diabetes Mellitus: Risks and Management during and after Pregnancy. Nat. Rev. Endocrinol. 2012, (8), 639–649.
16. Crowther, C.A.; Hiller, J.E.; Moss, J.R.; McPhee, A.J.; Jeffries, W.S.; Robinson, J.S.; Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N. Engl. J. Med. 2005, (352), 2477–2486.
17. C. Bitter, K. Suter-Zimmermann and C. Surber, “Nasal drug delivery in humans.”Curr. Problem Dermatol., 2011,(40), 20–35.
18. L. Illum, “Nasal drug delivery—possibilities, problems and solutions.” J. Controlled Release, 2003, 87, 187–198.
19. D. J. Pillion, M. D. Fryberg and E. Meezan “Nasal absorption of mixtures of fast-acting and long-acting insulins.” Int. J. Pharm, 2010, 388, 202–208.
20. P. Strong, K. Ito, J. Murray and G. “ Rapeport, Current approaches to the discovery of novel inhaled medicine.” Drug Discovery Today, 2018, 23, 1705–1717.
21. X. Duan and S. Mao, “New strategies to improve the intra nasal absorption of insulin” Drug Discovery Today, 2010, (15), 416-427.
22. M. Amidi, S. G. Romeijn, G. Borchard, H. E. Junginger, W. E. Hennick and W. Jiskoot, “Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system.” J. Controlled Release,2006;(11), 107-111.
23. D. J. Pillion, M. D. Fryberg and E. Meezan “Nasal absorption of mixtures of fast-acting and long-acting insulins.” Int. J. Pharm, 2010, 388, 202–208.
24. V. Schmid, S. Kullmann, W. Gfro¨rer, V. Hund, M. Hallschmid, H.-P. Lipp, H.-U. Ha¨ring, H. Preissl, A. Fritsche and M. Heni, “Safety of intranasal human insulin: A review, Diabete”. Obes. Metal, 2018, 20, 1563–1577.
25. Rejinold NS, Shin JH, Seok HY, Kim YC. Biomedical Applications of Microneedles in Therapeutics: Recent Advancements and Implications in Drug Delivery. Expert Opinion on Drug Delivery 13, 109-131 (2016).
26. Patton, J. S., & Byron, P. R.Inhaling medicines: delivering drugs to the body through the lungs. Nature Reviews Drug Discovery, 2007; 6(1), 67-74.
27. Laube, B. L.The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respiratory Care, 2005;50(9), 1161-1176.
28. Liu, Y., & Zhang, Y. Buccal mucosa as a route for systemic drug delivery: a review. Journal of Drug Delivery Science and Technology, 2013;23(1):73-80.
29. Owens, D. R., Zinman, B., & Bolli, G.Alternative routes of insulin delivery. Diabetic Medicine, 2001;18(10), 832-844.
30. Norris, S. L., Engelgau, M. M., & Narayan, K. M. V,“Effectiveness of self-management training in type 2 diabetes: A systematic review of randomized controlled trials.” Diabetes Care, 2001;24(3), 561-587.
31. Bailey, C. J., & Day, C. Management of Diabetes Mellitus: Addressing Health Literacy and Numeracy in Patient Care. Diabetes, Obesity and Metabolism, 2023;25(7), 1561-1571.
32. Dholariya S, Dutta S, Singh R, Parchwani D, Sonagra A, Kaliya M. “Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis.”Expert Opinion on Pharmacotherapy. 2023;24(18):2187-2198.
33. Thakkar S, Chopra A, Nagendra L, Kalra S, Bhattacharya S. “Teplizumab in type 1 diabetes mellitus: an updated review.” TouchREVIEWS in endocrinology. 2023;19(2):22-25.
34. Forzano I, Varzideh F, Avvisato R, Jankauskas SS, Mone P, Santulli G. “Tirzepatide: A systematic update”. International Journal of Molecular Sciences. 2022;23(23):131-135.
35. Singh, Awadhesh Kumar, Akriti Singh, Ritu Singh, and Anoop Misra. "Finerenone in diabetic kidney disease: A systematic review and critical appraisal." Diabetes & Metabolic Syndrome: Clinical Research & Reviews,2022;(16) 102-638
36. Konkwo C, Perry RJ. “Imeglimin: current development and future potential in type 2 diabetes.” J.controlled Release 2021;81(2):185-190.
37. Gallwitz, B. “Clinical Use of DPP-4 Inhibitors.” Frontiers in Endocrinology, 2020;23(11);30-35.
38. Smith A, Jones B. "The role of combination therapy with dapagliflozin, saxagliptin, and metformin in the management of type 2 diabetes." Diabetes, Obesity and Metabolism. 2020;22(5):678-684.
39. Goldenberg, R.M. and Steen, O., “ Semaglutide: review and place in therapy for adults with type 2 diabetes.” Canadian journal of diabetes, 2019,43(2),136-145.
40. Rendell, Marc S. "Albiglutide for the management of type 2 diabetes." Expert review of endocrinology & metabolism ,2018;13(1)1-8.
41. Handelsman, Y., Muskiet, M.H. and Meneilly, G.S., “Combining GLP-1 receptor agonists and basal insulin in older adults with type 2 diabetes: focus on lixisenatide and insulin glargine.” Advances in therapy, 2016. (36), pp.3321-3339.
42. Lean ME, Leslie WS, Barnes AC, et al. “Primary care-led weight management for remission of type 2 diabetes (DIRECT): an open-label, cluster-randomised trial”. Lancet. 2023; 391(10120): 541-551.
43. Hawa MI, Kolb H, Schloot N, et al. “Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype.” Diabetes Care. 2013;(36):908–913.
44. Bell RA, Meyer-Davis EJ, Beyer JW, et al. “Diabetes in non-H ispanic white youth”. Diabetes Care. 2009;32(Suppl2):102–111. .
45. Tamborlane WV, Klingensmith G. Crisis in care: “limited treatment options for type 2 diabetes in adolescents and youth.” Diabetes Care. 2013;(3),1777–1778.
46. Rubio-Cabezas O, Hattersley AT, Njolstad PR, Clinical Practice Consensus Guidelines ISPAD, et al. “The diagnosis and management of monogenic diabetes in children and adolescents.” Pediatr Diabetes. 2014;(15),47-64
47. Huxley RR, Peters SA, Mishra GD, “Woodward M. Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis.” Lancet Diabetes Endocrinol. 2015;3(3):198–206
48. Barker, S. P., & Klonoff, D. C,“Diabetes management apps: Empowering patients and enhancing care.” Journal of Diabetes Science and Technology, 2023;17(1), 45-53.
49. Vergès B “ Cardiovascular disease in type 1 diabetes: A review of epidemiological data and underlying mechanisms”. Diabetes Metab. 2020;(28):1262–3636.
50. Kovatchev, B. P., & Cobelli, C. (2022). Technology in Diabetes Management: Smart Insulin Pens and Mobile Health Applications. Diabetes Technology & Therapeutics, 2022;24(5), 327-335.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Vandana Kathiriya
Khyati College of Pharmacy, Palodia, Ahmedabad
Dr. Nishkruti Mehta
Associate Professor & Head, Department of Pharmacology, Palodia, Ahmedabad.
Dr. Praganesh Patani
Principal, Khyati College of Pharmacy, Palodia, Ahmedabad.